Account
Poster
15.10.2025
Budget impact minimisation approaches used across ...

Objectives: The market entry of effective obesity medications offers promise to patients with obesit...

Read more
News
01.09.2025
US Biotech, what is the latest on Trump’s two â€...

To date, there are two different levers in play under Trump’s “Most Favored Nation”, 1. A drug...

Read more
Articles
30.07.2025
Crossing the Atlantic: What US Biotech Needs to Kn...

For decades, the free market model of the US healthcare system has been very attractive for biotech ...

Read more
28.02.2025
Unlocking Access: The Role of Patient Engagement i...

AUTHORS: ​Joyce Atim, Rahul Vadehra​ Rare diseases have a significant impact on people worldwide...

Read more
Articles
17.09.2024
Can Real-World Evidence overcome uncertainty in Ra...

We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...

Read more
Articles
10.09.2024
Strategic approaches to achieving HTA approval for...

Achieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...

Read more
Insider Insights
05.09.2024
NICE’s 1000th Appraisal: Iptacopan for Paroxysma...

The recent appraisal by the National Institute for Health and Care Excellence (NICE) for Iptacopan, ...

Read more
News
03.09.2024
World Orphan Drug Congress Europe 2024

We're thrilled to announce our participation at World Orphan Drug Congress Europe 2024 in Barcelona ...

Read more
Insider Insights
08.08.2024
World’s first CRISPR-based Gene Therapy Exa-cel ...

NICE recommends gene therapy for severe beta-thalassaemia, offering hope for improved quality of lif...

Read more
News
13.02.2024
World EPA Congress 2024

The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.